viimane versioon :
19/11/2024
vähiravimite   Dactinomycin  
Süsteravim
Stabiilsus lahustes Stabiilsust mõjutavad tegurid stabiilsust mõjutavad faktorid Sobimatus Manustamis viis Viited pdf
   keemiline struktuur  

Kaubanduslikud nimed erinevates maades   Kaubanduslikud nimed erinevates maades     

Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist

Cosmegen Ameerika ühendriigid, Argentiina, Austraalia, Austria, Iraan, Itaalia, Kanada, Kreeka, Malaisia, Mehhiko, Norra, Prantsusmaa, Rootsi, Soome, Sveits, uus-Meremaa
Cosmegen Lyovac Iirimaa, Rumeenia, Suurbritannia
Dacilon India, Maroko, Tšiili
Dacmozen India
Dactino India
Dactinomicina Ecuador, Kolumbia, Maroko, Tšiili
Dactinomycin uus-Meremaa
Lyovac Cosmegen Belgia, Holland, Luksemburg, Saksamaa
Viited   Süsteravim   Viited : Dactinomycin  
tüüp avaldamine
3 ajaleht Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
84 ajaleht Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 ajaleht Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169 ajaleht Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 ajaleht Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
244 ajaleht Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 ajaleht Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307 ajaleht Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
334 ajaleht Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 ajaleht Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
492 ajaleht Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
729 ajaleht Rusmin S, Welton S, DeLuca P, DeLuca PP.
Effect of inline filtration on the potency of drugs administered intravenously.
Am J Hosp Pharm 1977 ; 34: 1071-1074.
857 ajaleht Kanke M, Eubanks JL, DeLuca PP.
Binding of selected drugs to a “treated” inline filter.
Am J Hosp Pharm 1983 ; 40: 1323-1328.
905 ajaleht Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
1178 ajaleht Benvenuto JA, Anderson RW, Kerkof K, Smith RG, Loo TL.
Stability and compatibility of antitumor agents in glass and plastic containers.
Am J Hosp Pharm 1981 ; 38: 1914-1918.
1322 ajaleht Ennis CE, Merritt RJ, Neff DN.
In vitro study of inline filtration of medications commonly administered to pediatric cancer patients.
JPEN 1983 ; 7: 156-158.
1410 ajaleht Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1423 ajaleht Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
4153 Labor Dactinomycin (Cosmegen Lyovac®) - Summary of Product Characteristics
Orphan Europe (UF) Limited 2014

  Mentions Légales